SAT1 and cancer: Among them, Nano11047 effectively induces SAT1 and SMOX enzymatic activities and hampers cancer cell survival and growth in preclinical models (Reddy et al., 1998; Kuo et al., 2009; Smith et al., 2011; Murray-Stewart et al., 2017) and is now being evaluated in clinical trials (www.clinicaltrials.org).